Previous close | 3,450.00 |
Open | 3,411.70 |
Bid | 3,591.00 x 100 |
Ask | 0.00 x 100 |
Day's range | 3,450.00 - 3,450.00 |
52-week range | 3,286.00 - 5,557.95 |
Volume | |
Avg. volume | 72 |
Market cap | 522.523B |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 25.06 |
EPS (TTM) | 137.66 |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.